natgillin/translations-raw huggingface dataset:
The incidence of adverse events is as expected and most commonly involves the gastrointestinal tract.
Pojavnost neželenih učinkov je pričakovana, najpogosteje pa vključujejo prebavila.
During the review process the superior efficacy of the fixed dose combination were compared to each mono-component.
Med pregledom so primerjali učinkovitost fiksne kombinacije odmerkov s posamičnima komponentama.
The data obtained in AFT-MX-1 is reinforced by the large Phase III efficacy study AFT-MX-6.
Podatke, pridobljene v študiji AFT-MX-1, dodatno potrjuje velika študija učinkovitosti III. faze AFT-MX-6.
• The Committee is also of the opinion that adequate information in order to minimise any risk of use outside of the recommended duration of use of maximum of 3 days has been included in the proposed product information and in the updated risk management plan, in this regard.
• odbor je prav tako menil, da so bile v predlagane informacije o zdravilu in posodobljen načrt za obvladovanje tveganja vključene ustrezne informacije za zmanjševanje tveganja za uporabo zunaj priporočenega, največ 3-dnevnega trajanja uporabe.
The main issues were the basis of the referral to CHMP which were that the rationale of the fixed dose combination is not considered justified, the additional benefit for this new fixed dose combination compared to the mono-components has not been demonstrated and that an acceptable safety profile of the new fixed-dose combination has not been shown.
Glavni pomisleki so bili osnova za napotitev na odbor CHMP, in sicer, da fiksna kombinacija odmerkov ni upravičena, da ni bila dokazana dodatna korist nove fiksne kombinacije odmerkov v primerjavi s posameznimi komponentami in da ni bil dokazan sprejemljiv varnostni profil nove fiksne kombinacije odmerkov.
CHMP members has expressed some concerns regarding the demonstrated superiority being limited to one post-operative pain model (molar extraction), that another pivot study failed to demonstrate the superiority of the association in another pain model (arthroscopy), and that there was no evidence available of superiority in the treatment of mild pain.
Članice odbora CHMP so izrazile nekaj pomislekov o dokazani superiornosti, ki je omejena le na en model pooperativne bolečine (ekstrakcija kočnikov), o dejstvu, da druga ključna študija ni dokazala superiornosti kombinacije na drugem bolečinskem modelu (artroskopija), in o odsotnosti razpoložljivih dokazov o superiornosti pri zdravljenju blage bolečine.
The results showed that the combination of paracetamol and ibuprofen had greater analgesic efficacy than the same dose of ibuprofen alone.
Rezultati so pokazali, da ima kombinacija paracetamola in ibuprofena večjo analgetično učinkovitost kot enak odmerek samega ibuprofena.
With regards the safety of this fixed dose combination, following the assessment of the data in the clinical trials as well as the PSUR and an extensive search of the published literature concluded that the known safety outcomes are expected by concomitant use of ibuprofen and paracetamol compared with the mono-components alone.
Kar zadeva varnost te fiksne kombinacije odmerkov, je bilo po ocenjevanju podatkov iz kliničnih preskušanj in poročil PSUR ter obširnem iskanju po objavljeni literaturi zaključeno, da so znani varnostni izidi, pričakovani ob sočasni uporabi ibuprofena in paracetamola, primerljivi z uporabo posamičnih komponent.
Clinical trials with the fixed dose combination have also not indicated any other undesirable effects other than those known for paracetamol alone or ibuprofen alone).
Klinična preskušanja s fiksno kombinacijo odmerkov niso pokazala drugih neželenih učinkov kot tistih, ki so že znani za sam paracetamol ali sam ibuprofen.
The CHMP also recommended the short term use (max for 3 days) of this fixed dose combination.
Odbor CHMP je tudi priporočil kratkotrajno uporabo (največ 3 dni) te fiksne kombinacije odmerkov.
Thirdly, there is a medical need for a new fixed dose combination analgesic that does not contain an opioid component for relief of acute pain.
Tretjič, za lajšanje akutne bolečine obstaja zdravstvena potreba po novem analgetiku s fiksno kombinacijo odmerkov, ki ne vsebuje opioidne komponente.
Having considered the above, the CHMP has recommended by majority the granting of the marketing authorisation for which the summary of product characteristics, labelling and package leaflet was amended following the final version achieved during the Coordination group procedure as mentioned in Annex III for Paracetamol/ibuprofen 500 mg / 150 mg film coated tablets and associated names fixed dose combination.
Z upoštevanjem zgoraj navedenega je odbor CHMP večinsko priporočil odobritev dovoljenja za promet z zdravilom, za katerega so bili povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo posodobljeni po končni različici, dogovorjeni v postopku Skupine za usklajevanje, kot je navedeno v Prilogi III za zdravilo s fiksno kombinacijo odmerkov Paracetamol/ibuprofen 500 mg/150 mg filmsko obložene tablete in povezana imena.
This phase II exploratory study has shown that in osteoarthritis pain, the combination is effective.
faze je pokazala, da je kombinacija pri bolečini zaradi osteoartritisa učinkovita.
Instructions in the posology section and warnings for the duration of use were provided in the product information.
Navodila v poglavju o odmerjanju in opozorila glede trajanja uporabe so bila vključena v informacije o zdravilu.
Furthermore in a study population which included 1.2 million patients, whose aim was to evaluate and compare the risk of specific safety outcomes in patients prescribed ibuprofen and paracetamol concomitantly with those in patients prescribed ibuprofen or paracetamol alone, concluded that the known risk of the safety outcomes examined does not appear to be modified by concomitant use of ibuprofen and paracetamol compared with the mono-components alone.
V študiji s populacijo, ki je vključevala 1,2 milijona bolnikov, katere cilj je bil ovrednotiti in primerjati tveganje za določene varnostne izide pri bolnikih, ki jim je bil sočasno predpisan ibuprofen in paracetamol, in pri bolnikih, ki jim je bil predpisan samo ibuprofen ali paracetamol, so zaključili, da ne kaže, da bi sočasna uporaba ibuprofena in paracetamola spremenila znano tveganje za preučene varnostne izide v primerjavi s posamičnima komponentama.
Vale Pharmaceuticals submitted to the United Kingdom an application under the decentralised procedure (DCP) for Paracetamol 500mg and Ibuprofen 150mg fixed dose combination on 27 March 2015.
Družba Vale Pharmaceuticals je 27. marca 2015 Združenemu kraljestvu predložila vlogo po decentraliziranem postopku za zdravilo s fiksno kombinacijo odmerkov paracetamola 500 mg in ibuprofena 150 mg.
Study AFT -MX6 was another phase III, placebo-controlled, prospective, randomised, double-blind, parallel-design trial with a safety follow-up at Day 30.
Študija AFT -MX6 je bila še eno s placebom nadzorovano, prospektivno, randomizirano, dvojno slepo preskušanje III. faze z vzporedno zasnovo, v katerem so varnost spremljali do 30. dneva.
Male and female participants aged 18 and 60 years undergoing surgical removal of least two impacted third molars were eligible for this study.
Za to študijo so bili primerni udeleženci in udeleženke, stari od 18 do 60 let, ki so jim kirurško odstranili vsaj dva impaktirana tretja kočnika.
When comparing with past users, for most safety outcomes, current users of concomitant paracetamol and ibuprofen had relative rates between those for current users of ibuprofen alone and paracetamol alone.
Primerjalno z nekdanjimi uporabniki so bili relativni deleži večine varnostnih izidov pri trenutnih sočasnih uporabnikih paracetamola in ibuprofena med deleži pri trenutnih uporabnikih samega ibuprofena in samega paracetamola.
Its objective was to compare the analgesic effects and safety of paracetamol and ibuprofen combined versus paracetamol alone or ibuprofen alone in adults with postoperative pain.
Njen cilj je bil primerjati analgetični učinek in varnost kombinacije paracetamola in ibuprofena s samim paracetamolom ali samim ibuprofenom pri odraslih s pooperativno bolečino.
Its objective was to compare the analgesic efficacy and clinical safety of Combination (paracetamol 500mg and ibuprofen 150 mg) with the other 3 treatment groups (paracetamol 500 mg; low dose ibuprofen 150 mg; high dose ibuprofen 300mg) in patients who have painful osteoarthritis of the knee.
Njen cilj je bil primerjati analgetično učinkovitost in klinično varnost kombinacije (paracetamol 500 mg in ibuprofen 150 mg) z drugimi tremi skupinami zdravljenja (paracetamol 500 mg, majhen odmerek ibuprofena 150 mg, velik odmerek ibuprofena 300 mg) pri bolnikih z bolečim osteoartritisom kolena.
The CHMP accepted this justification by the applicant for the need for the fixed dose combination in short term treatment of acute pain is acceptable for the several reasons.
Odbor CHMP je sprejel predlagateljevo utemeljitev, da je fiksna kombinacija odmerkov pri kratkotrajnem zdravljenju akutne bolečine sprejemljiva zaradi več razlogov.
The CHMP was of the opinion that the benefit-risk balance of Paracetamol / ibuprofen 500 mg / 150 mg film coated tablets and associated names fixed dose combination is considered to be favourable when used in accordance with the terms of the product information.
Odbor CHMP je menil, da velja razmerje med tveganji in koristmi zdravila s fiksno kombinacijo odmerkov Paracetamol/ibuprofen 500 mg/150 mg filmsko obložene tablete in povezanih imen za ugodno, če se uporablja v skladu s pogoji v informacijah o zdravilu.
Appropriately, instructions in the posology section and warnings for the duration of use were provided in the product information.
Navodila v poglavju z odmerjanjem in opozorila glede trajanja uporabe so bila ustrezno vključena v informacije o zdravilu.
Overall benefit-risk balance
Skupno razmerje med tveganji in koristmi
The rationale of the applicant presented the need for the fixed dose combination in short term treatment of acute pain was presented to the CHMP.
Odboru CHMP je bila predložena predlagateljeva utemeljitev, v kateri je predstavil potrebo po fiksni kombinaciji odmerkov pri kratkotrajnem zdravljenju akutne bolečine.
Rescue medication consumption was accounted for in the primary endpoint analysis by carrying forward the pre-rescue VAS pain score.
Pri analizi primarnega opazovanega dogodka so upoštevali uporabo reševalnega zdravila, tako da so v nadaljevanju upoštevali jakost bolečine po vizualni analogni lestvici pred uporabo reševalnega zdravila.
This phase III study was designed as a prospective, parallel-group, double-blind, placebo comparison of the clinical efficacy and safety of fixed dose combination (2 tablets, each tablet containing 500 mg paracetamol and 150 mg ibuprofen) versus its individual components (either 1000 mg paracetamol or 300 mg ibuprofen) and versus placebo in 300 patients suffering of moderate to severe pain due to post-arthroscopy surgery of the knee.
Ta študija III. faze je bila zasnovana kot prospektivna, dvojno slepa študija z vzporednimi skupinami in placebom, v kateri so primerjali klinično učinkovitost in varnost fiksne kombinacije odmerkov (2 tableti, vsaka je vsebovala 500 mg paracetamola in 150 mg ibuprofena) v primerjavi s posamičnima komponentama (1 000 mg paracetamola ali 300 mg ibuprofena) in v primerjavi s placebom pri 300 bolnikih, ki so imeli zmerno do hudo bolečino po artroskopskem posegu na kolenu.
In conclusion, the known risk of the safety outcomes examined does not appear to be modified by concomitant use of ibuprofen and paracetamol compared with paracetamol or ibuprofen alone.
Kaže torej, da se znano tveganje za preučene varnostne izide s sočasno uporabo ibuprofena in paracetamola v primerjavi s samim paracetamolom ali ibuprofenom ne spremeni.
• The Committee reviewed all the data submitted by the applicant in support of the efficacy of Paracetamol/ibuprofen 500 mg / 150 mg film coated tablets and associated names fixed dose combination in short-term symptomatic treatment of mild to moderate pain.
• odbor je pregledal vse podatke, ki jih je predložil predlagatelj v podporo učinkovitosti zdravila s fiksno kombinacijo odmerkov Paracetamol/ibuprofen 500 mg/150 mg filmsko obložene tablete in povezanih imen pri kratkotrajnem simptomatskem zdravljenju blage do zmerne bolečine;
Study AFT-MX-1 was a phase III, pivotal study with a prospective, parallel group, double-blind comparison of the analgesic effect of a combination of paracetamol and ibuprofen, paracetamol alone, or ibuprofen alone in patients with postoperative pain.
Študija AFT-MX-1 je bila ključna, prospektivna, dvojno slepa študija III. faze z vzporednimi skupinami, v kateri so primerjali analgetični učinek kombinacije paracetamola in ibuprofena, samega paracetamola ali samega ibuprofena pri bolnikih s pooperativno bolečino.
The CHMP requested that specifically for the special populations of hepatic and renal impaired patients the warnings related to paracetamol use are all in line with the warnings existing in the mono-component's product information, for completeness of the safety information.
Odbor CHMP je zaradi zagotavljanja celovitosti informacij o varnosti zahteval, da morajo biti opozorila za posebne populacije bolnikov z jetrno ali ledvično okvaro glede uporabe paracetamola v skladu z obstoječimi opozorili v informacijah o zdravilu z eno samo komponento.
The important safety risk associated with prolonged use of paracetamol and ibuprofen are well known and are hepatotoxicity, peptic ulceration and gastrointestinal bleeding, nephrotoxicity, cardiac, cardiovascular and cerebrovascular effects .The applicant has provided a comprehensive review of the safety data both from the submitted studies and from overall pooled study data including the exposure of the combination in elderly patients.
Pomembna varnostna tveganja, povezana z dolgotrajno uporabo paracetamola in ibuprofena, so dobro znana in vključujejo hepatotoksičnost, peptične ulkuse in krvavitev iz prebavil, nefrotoksičnost ter srčne, kardiovaskularne in cerebrovaskularne učinke.
• The Committee is of the opinion that the available data is supportive of the efficacy of Paracetamol/ibuprofen 500 mg / 150 mg film coated tablets and associated names fixed dose combination in short-term symptomatic treatment of mild to moderate pain.
• odbor je mnenja, da razpoložljivi podatki podpirajo učinkovitost zdravila s fiksno kombinacijo odmerkov Paracetamol/ibuprofen 500 mg/150 mg filmsko obložene tablete in povezanih imen pri kratkotrajnem simptomatskem zdravljenju blage do zmerne bolečine;
The short term use (max for 3 days) of this fixed dose combination has been recommended by the CHMP and accepted by the applicant.
Odbor CHMP je priporočil kratkotrajno uporabo (največ 3 dni) te fiksne kombinacije odmerkov, kar je predlagatelj sprejel.
Study AFT-MX-3 was a dose response study and a double-blind, placebo-controlled, randomised, parallel group comparison of the effects of different paracetamol and ibuprofen combination doses and placebo in participants with pain from removal of 2-4 third molars.
Študija AFT-MX-3 je bila študija odzivnosti na odmerke in dvojno slepa, s placebom nadzorovana, randomizirana študija z vzporednimi skupinami, v kateri so primerjali učinke različnih odmerkov kombinacije paracetamola in ibuprofena ter placeba pri udeležencih z bolečino zaradi izdrtja 24 tretjih kočnikov.
In conclusion, the safety outcomes examined were consistent in the concomitant use of ibuprofen and paracetamol compared with paracetamol or ibuprofen alone.
Preučeni varnostni izidi pri sočasni uporabi ibuprofena in paracetamola v primerjavi s samostojno uporabo paracetamola ali ibuprofena so bili torej skladni.
Therefore the risk for prolonged use of the fixed dose combination and Paracetamol or Ibuprofen alone should have a similar risk/benefit profile.
Zato bi moralo biti razmerje med koristmi in tveganji fiksne kombinacije odmerkov in samega paracetamola ali ibuprofena podobno.
Study AFT-MX-6E was a phase III trial in another acute pain model (arthroscopy).
Študija AFT-MX-6E je bilo preskušanje II.
Study AFT-MX-4 was a phase II exploratory study with a double-blind, randomized, parallel group comparison of the effects of Paracetamol and Ibuprofen Combined with Paracetamol, Low and High Dose Ibuprofen on Patients with Pain from Osteoarthritis of the Knee, and a 12 month open label extension.
faze, ki je vključevala randomizirano, dvojno slepo študijo z vzporednimi skupinami, v kateri so primerjali učinke kombinacije paracetamola in ibuprofena z učinki paracetamola ter majhnimi in velikimi odmerki ibuprofena pri bolnikih z bolečino zaradi osteoartritisa kolena, in 12-mesečno odprto podaljšanje.
Paracetamol and ibuprofen are two analgesic compounds with long histories of clinical use and both have been shown to be safe and well tolerated at maximum recommended daily doses.
Paracetamol in ibuprofen sta analgetični spojini z dolgoletno klinično uporabo.
Annex II Scientific conclusions
Ta raziskovalna študija II.
The applicant was requested to provide the following information: 1.
Odbor je od predlagatelja zahteval naslednje informacije: 1.
CVMP started the procedure on 6 November 2007.
Odbor CVMP je s postopkom začel dne 6. novembra 2007.
3421 GW Oudewater The Netherlands
3421 GW Oudewater Nizozemska
In response to question 2, the applicant pointed out that there are no differences at all that would justify different conclusions on the safety and efficacy for the two products.
V odgovor na 2. vprašanje je predlagatelj poudaril, da ni nikakršnih razlik, ki bi utemeljile različne zaključke o varnosti in učinkovitosti obeh zdravil.
France considers that the dosing regime of the product is not correct.
Francija meni, da urnik odmerjanja zdravila ni pravilen.
A list of questions was adopted on 8 November 2007 and sent to the marketing authorisations holders (MAH), by which the procedure clock was stopped.
Seznam vprašanj je bil sprejet dne 8. novembra 2007 in poslan imetnikom dovoljenja za promet (MAH), s čimer se je merjenje časa za postopek ustavilo.
The aim of the assessment is to establish whether marketing authorisations of veterinary medicinal products included in the referral procedure should be maintained, suspended, varied or revoked with view to the grounds for referral.
Cilj ocenjevanja je ugotoviti, ali naj se dovoljenja za promet z zdravili za uporabo v veterinarski medicini, ki so vključena v napotitveni postopek, obdržijo, kakršna so, zadržijo, spremenijo ali prekličejo glede na razloge za napotitev.
This may lead to lack of efficacy and furthering resistance development in target pathogens, which could possibly lead to risks to human health where zoonotic bacteria are concerned.
To lahko privede do pomanjkljive učinkovitosti in nadaljnjega razvoja odpornosti ciljnih patogenih organizmov, kar bi lahko v primeru zoonoznih bakterij povzročilo tudi tveganje za človeško zdravje.
horse oral
konj peroralno
5 mg trimethoprim and 25 mg sulfadiazine per kg body weight per day to a maximum of 5 days.
5 mg trimetoprima in 25 mg sulfadiazina na kg telesne mase na dan do največ pet dni
The valid Summary of Product Characteristics, labelling and package leaflet are the versions agreed by the Reference Member State and Concerned Member States (except France) at day 210 of the decentralised procedure.
Veljavni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so različice, s katerimi se so referenčna država članica in zadevne države članice (z izjemo Francije) strinjale na 210. dan decentraliziranega postopka.
The original reference product "Tribrissen Oral Paste" was authorised in the Netherlands in 1992.
Originalno referenčno zdravilo “Tribrissen peroralna pasta” je bilo na Nizozemskem odobreno leta 1992.
333.3 mg/g sulfadiazine and 66.7 mg/g trimethoprim.
333,3 mg/g sulfadiazina in 66,7 mg/g trimetoprima.
In response to question 1, the applicant provided a copy of the original dossier as submitted in support of the application of a decentralised procedure, and any supplementary data submitted during the decentralised procedure in response to the phase I and phase II assessment and the referral procedure in CMD(v) thereafter.
V odgovor na 1. vprašanje je predlagatelj priskrbel kopijo originalnega dosjeja, predloženega v podporo uporabi decentraliziranega postopka, in vse dodatne podatke, ki so bili predloženi med decentraliziranim postopkom v odgovor na I. in II.
The objections raised by France should not prevent the granting of a marketing authorisation for Equibactin vet.
Zadržki, ki jih je imela Francija, ne bi smeli preprečiti odobritve dovoljenja za promet z zdravilom Equibactin vet. peroralna pasta.
Under these conditions the applicant is exempted from submitting further preclinical or clinical data on efficacy of the proposed product, and can claim the same indications for use and the same precautionary warnings to ensure safe use for the product as for the reference product Tribrissen Oral Paste.
Pod temi pogoji predlagatelju ni potrebno predložiti nadaljnjih predkliničnih ali kliničnih podatkov o učinkovitosti predlaganega zdravila in lahko uveljavlja iste indikacije za uporabo in ista previdnostna opozorila za zagotovitev varne uporabe zdravila kot za referenčno zdravilo Tribrissen oralna pasta.
The Netherlands, reference member state in the decentralised procedure, notified the EMEA on 24 September 2007 that the Co-ordination Group for Mutual Recognition and Decentralised ProceduresVeterinary (CMD(v)) failed to reach an agreement for Equibactin vet. (333 mg/g + 67 mg/g) Oral Paste for Horses.
Nizozemska, referenčna država članica, je v decentraliziranem postopku dne 24. septembra 2007 obvestila agencijo EMEA, da Koordinacijska skupina za medsebojno prepoznavanje in decentralizirane postopke - veterina (CMD(v) ni dosegla sporazuma o zdravilu Equibactin vet. (333 mg/g + 67 mg/g) peroralna pasta za konje.
Frequency and route of administration
Pogostost in način uporabe zdravila
On 16 November 2007 responses to the questions were received from MAH and the clock restarted.
Dne 16. novembra 2007 je Odbor od imetnikov dovoljenja za promet prejel odgovore na vprašanja, zato so z merjenjem časa nadaljevali.
ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER
DODATEK I IME, FARMACEVTSKA OBLIKA, JAKOST ZDRAVILA, ŽIVALSKA VRSTA, NAČIN UPORABE ZDRAVILA IN IMETNIK DOVOLJENJA ZA PROMET
Consequently, the conclusions on efficacy and safety for the reference product, Tribrissen oral paste, can be extended to the generic product, Equibactin vet.
Posledično je mogoče zaključke o učinkovitosti in varnosti referenčnega zdravila Tribrissen oralna pasta razširiti na generično zdravilo Equibactin vet. peroralna pasta.
Applicant or Marketing
Predlagatelj ali imetnik dovoljenja za promet z zdravilom
Pursuant to Article 33(4) of Council Directive 2001/82/EC, as amended, the matter was referred to the CVMP.
Zadeva je bila skladno s členom 33(4) Direktive Sveta 2001/82/ES, kakor je bila spremenjena, napotena na Odbor za zdravila za uporabo v veterinarski medicini (CVMP).
Equibactin vet. (333 mg/g + 67 mg/g) Oral Paste for Horses.
Equibactin vet. (333 mg/g + 67 mg/g) peroralna pasta za konje.
CVMP noted that Equibactin vet. (333 mg/g + 67 mg/g) Oral Paste for Horses is a generic of Tribrissen oral paste (authorised in the Netherlands) and that the concerns raised by France can only be addressed in the framework of this procedure, in case any differences between both products would justify different conclusions on the safety or efficacy.
Odbor CVMP je ugotovil, da je zdravilo Equibactin vet. (333 mg/g + 67 mg/g) peroralna pasta za konje generično zdravilo, ki izhaja iz zdravila Tribrissen peroralna pasta (odobreno na Nizozemskem), in da je mogoče na zadržke, ki jih je imela Francija, odgovoriti le v okviru tega postopka, če bi kakršna koli razlika med obema zdraviloma utemeljila različne zaključke o varnosti ali učinkovitosti.